Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Recruiting · NCT04265872 · Registry updated 2026-02-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Early phase 1 | 2026-02-12 | NCT04265872 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Baylor Research Institute | 66 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor University Medical Center, Baylor Charles A Sammons Cancer Center | Dallas | United States | 4 |